



**National Marrow  
Donor Program®**

Entrusted to operate the  
C.W. Bill Young  
Cell Transplantation Program

**National Coordinating Center**  
3001 Broadway St. N.E.  
Suite 100  
Minneapolis, MN 55413-1753

Toll Free: 1 (800) 526-7809  
Phone: (612) 627-5800  
[marrow.org](http://marrow.org)

**Board of Directors**

Robert D. Lorentz, Ph.D. – Chair  
Edward L. Snyder, M.D. – Chair-elect  
Naynesh R. Kamani, M.D. – Vice Chair  
Jacquelyn Fredrick – Secretary  
Daniel D. Arndt  
Laurence D. Atlas, Esquire  
Theresa M. Boyd, M.D.  
Arthur W. Bracey, M.D.  
Airam da Silva, M.P.H.  
Stella M. Davies, M.B. B.S., Ph.D.  
Andrea Feldmar  
Sergio A. Giralt, M.D.  
Gregory Hale, M.D.  
Robert Howard  
Dave Huddleston  
Rebecca A. Lewis, Esquire  
Mary Faith Marshall, Ph.D.  
Rebecca McCullough  
Adam C. McFadden  
Edgar Milford, M.D.  
Esperanza B. Papadopoulos, M.D.  
Stelios Papadopoulos Ph.D.  
Thomas H. Price, M.D.  
Susan L. Rossmann, M.D., Ph.D.  
Randal K. Wada, M.D.  
John P. Whiteley  
John R. Wingard, M.D.

Jeffrey W. Chell, M.D.  
Chief Executive Officer

November 17, 2008

Cdr. Elizabeth Montcalm-Smith  
Office of Naval Research (ONR 342)  
875 N. Randolph St.  
Arlington, VA 22203-1995

Subject: Quarterly Performance/Technical Report of the National  
Marrow Donor Program®

Reference: Grant Award #N00014-08-1-0058 between the Office of  
Naval Research and the National Marrow Donor Program

Dear Cdr. Montcalm-Smith:

Enclosed is subject document which provides the performance activity for  
each statement of work task item of the above reference for the period of  
July 1, 2008 to September 30, 2008.

Should you have any questions as to the scientific content of the tasks and  
the performance activity of this progress report, you may contact our Chief  
Medical Officer – Dennis L Confer, MD directly at 612-362-3425.

With this submittal of the quarterly progress report, the National Marrow  
Donor Program has satisfied the reporting requirements of the above  
reference for quarterly documentation. Other such quarterly documentation  
has been previously submitted under separate cover.

Please direct any questions pertaining to the cooperative agreement to my  
attention (612-362-3403 or at [cabler@nmdp.org](mailto:cabler@nmdp.org)).

Sincerely,

A handwritten signature in blue ink that reads "Carla Abler-Erickson".

Carla Abler-Erickson, MA  
Sr. Contracts Representative

Enclosure: Quarterly Report with SF298

C: D. Ivery – ACO (ONR-Chicago), letter  
Dr. Robert J. Hartzman, CAPT, MC, USN (Ret): letter  
Jennifer Ng, PhD – C.W. Bill Young Marrow Donor Recruitment and  
DTIC (Ste 0944): letter and enclosure  
J. Rike - DTIC (Ste 0944): letter  
NRL (Code 5227): letter  
Dennis Confer, MD, Chief Medical Officer, NMDP, letter only  
Michelle Setterholm, NMDP letter only

|  |                         |                                    |   |  |   |
|--|-------------------------|------------------------------------|---|--|---|
| <b>REPORT DOCUMENTATION PAGE</b>   |                         |                                    |   | <b>Form Approved<br/>OMB No. 0704-0188</b>                   |   |
| <small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.</small>  |                         |                                    |   |  |   |
| <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>  |                         |                                    |   |  |   |
| <b>1. REPORT DATE</b> (DD-MM-YYYY)<br>17-11-2008   |                         | <b>2. REPORT TYPE</b><br>Quarterly |   | <b>3. DATES COVERED</b> (From - To)<br>Jul – Sep 2008        |   |
| <b>4. TITLE AND SUBTITLE</b><br>Quarterly Performance / Technical Report   |                         |                                    |   | <b>5a. CONTRACT NUMBER</b><br>N/A                            |   |
|  |                         |                                    |   | <b>5b. GRANT NUMBER</b><br>N00014-08-1-0058                  |   |
|  |                         |                                    |   | <b>5c. PROGRAM ELEMENT NUMBER</b><br>N/A                     |   |
| <b>6. AUTHOR(S)</b><br>Setterholm, Michelle  |                         |                                    |   | <b>5d. PROJECT NUMBER</b><br>N/A                             |   |
|  |                         |                                    |   | <b>5e. TASK NUMBER</b><br>Project 1, 2, 3, 4                 |   |
|  |                         |                                    |   | <b>5f. WORK UNIT NUMBER</b><br>N/A                           |   |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br>National Marrow Donor Program<br>3001 Broadway St., N.E., Ste. 500<br>Minneapolis, MN 55413   |                         |                                    |   | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b><br>N/A       |   |
| <b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>Office of Naval Research<br>875 N. Randolph St.<br>Arlington, VA 22203   |                         |                                    |   | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b><br>ONR               |   |
|  |                         |                                    |   | <b>11. SPONSORING/MONITORING AGENCY REPORT NUMBER</b><br>N/A |   |
| <b>12. DISTRIBUTION AVAILABILITY STATEMENT</b><br>Approved for public release; distribution is unlimited   |                         |                                    |   |  |   |
| <b>13. SUPPLEMENTARY NOTES</b><br>N/A  |                         |                                    |   |  |   |
| <b>14. ABSTRACT</b><br><u>1. Contingency Preparedness:</u> Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan.<br><br><u>2. Rapid Identification of Matched Donors :</u> Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event.<br><br><u>3. Immunogenetic Studies:</u> Increase understanding of the immunologic factors important in HSC transplantation.<br><br><u>4. Clinical Research in Transplantation:</u> Create a platform that facilitates multicenter collaboration and data management. |                         |                                    |   |  |   |
| <b>15. SUBJECT TERMS</b><br>Research in HLA Typing, Hematopoietic Stem Cell Transplantation and Clinical Studies to Improve Outcomes   |                         |                                    |   |  |   |
| <b>16. SECURITY CLASSIFICATION OF:</b>   |                         |                                    | <b>17. LIMITATION OF ABSTRACT</b><br>Same as Report | <b>18. NUMBER OF PAGES</b><br>17                             | <b>19a. NAME OF RESPONSIBLE PERSON</b><br>Dennis L. Confer, MD – Chief Medical Office |
| <b>a. REPORT</b><br>U  | <b>b. ABSTRACT</b><br>U | <b>c. THIS PAGE</b><br>U           |   |  | <b>19b. TELEPHONE NUMBER (Include area code)</b><br>612.362.3425                      |

Grant Award N00014-08-1-0058

QUARTERLY  
PERFORMANCE / TECHNICAL REPORT  
FOR  
JULY 01, 2008 to SEPTEMBER 30, 2008

Office of Naval Research

And

The National Marrow Donor Program  
3001 Broadway Street N.E.  
Minneapolis, MN 55413  
1-800-526-7809

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

| <b>TABLE OF CONTENTS</b> |   |               |             |
|--------------------------|---|---------------|-------------|
| <b>TASK</b>              | <b>DESCRIPTION</b>  | <b>STATUS</b> | <b>PAGE</b> |
| <b>IIA</b>               | <b>Contingency Preparedness</b>                               |               |             |
| <b>IIA.1</b>             | <b>Hypothesis 1 – Care Plans by Transplant Physicians</b>     |               | 4           |
| IIA.1.1                  | Aim 1 – Secure Interest of Transplant Physicians              | Open          | 4           |
| IIA.1.2                  | Aim 2 – GCSF in Radiation Exposure                            | No Activity   | 4           |
| IIA.1.3                  | Aim 3 – Patient Assessment Guidelines and System Enhancements | Open          | 5           |
| IIA.1.4                  | Aim 4 – National Data Collection Model                        | Open          | 6           |
| <b>IIA.2</b>             | <b>Hypothesis 2 – Coordination of Care of Casualties</b>      |               | 6           |
| IIA.2.1                  | Aim 1 – Contingency Response Network                          | Open          | 6           |
| IIA.2.2                  | Aim 2 – Standard Operating Procedures                         | No Activity   | 7           |
| <b>IIA.3</b>             | <b>Hypothesis 3 – Information Technology Infrastructure</b>   |               | 7           |
| IIA.3.1                  | Aim 1 – I.S. Disaster Recovery                                | Open          | 7           |
| IIA.3.2                  | Aim 2 – Critical Facility and Staff Related Functions         | Open          | 7           |
| <b>IIB</b>               | <b>Rapid Identification of Matched Donors</b>                 |               |             |
| <b>IIB.1</b>             | <b>Hypothesis 1 – Resolution of Speeds Donor Selection</b>    |               | 8           |
| IIB.1.1                  | Aim 1 – Increase Registry Diversity                           | Open          | 8           |
| IIB.1.2                  | Aim 2 – Evaluate HLA-DRB1 High Resolution Typing              | Closed        | 8           |
| IIB.1.3                  | Aim 3 – Evaluate HLA-C Typing of Donors                       | Closed        | 8           |
| IIB.1.4                  | Aim 4 – Evaluate Buccal Swabs                                 | No Activity   | 8           |
| IIB.1.5                  | Aim 5 – Enhancing HLA Data for Selected Donors                | No Activity   | 8           |
| IIB.1.6                  | Aim 6 – Maintain a Quality Control Program                    | No Activity   | 8           |
| <b>IIB.2</b>             | <b>Hypothesis 2 – Improve HLA Quality &amp; Resolution</b>    |               | 9           |
| IIB.2.1                  | Aim 1 – Collection of Primary Data                            | Open          | 9           |
| IIB.2.2                  | Aim 2 – Validation of Logic of Primary Data                   | Closed        | 9           |
| IIB.2.3                  | Aim 3 – Reinterpretation of Primary Data                      | Closed        | 9           |
| IIB.2.4                  | Aim 4 – Genotype Lists & Matching Algorithm                   | No Activity   | 9           |
| <b>IIB.3</b>             | <b>Hypothesis 3 – Algorithm to Predict Best Donor</b>         |               | 9           |
| IIB.3.1                  | Aim 1 – Phase I of EM Haplotype Logic                         | No Activity   | 9           |
| IIB.3.2                  | Aim 2 – Enhancement of EM Algorithm                           | Open          | 9           |
| IIB.3.3                  | Aim 3 – Optimal Registry Size Analysis                        | Open          | 10          |
| IIB.3.4                  | Aim 4 – Target Underrepresented Phenotypes                    | Open          | 10          |
| IIB.3.5                  | Aim 5 – Bioinformatics Web Site                               | Closed        | 10          |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|              |   |             |    |
|--------------|---|-------------|----|
| IIB.3.6      | Aim 6 – Consultants to Improve Algorithm                                  | No Activity | 10 |
| <b>IIB.4</b> | <b>Hypothesis 4 – Reduction of Donor Matching Time</b>                    |             | 11 |
| IIB.4.1      | Aim 1 – Expand Network Communications                                     | Open        | 11 |
| IIB.4.2      | Aim 2 – Central Contingency Management                                    | Open        | 13 |
| IIB.4.3      | Aim 3 – Benchmarking Analysis   | Closed      | 13 |
| IIB.4.4      | Aim 4 – Expand Capabilities of Collection and Apheresis Centers           | No Activity | 13 |
| <b>IIC.</b>  | <b>Immunogenetic Studies</b>  |             |    |
| <b>IIC.1</b> | <b>Hypothesis 1 – Influence of HLA Mismatches</b>                         |             | 14 |
| IIC.1.1      | Aim 1 – Donor Recipient Pair Project                                      | Open        | 14 |
| <b>IIC.2</b> | <b>Hypothesis 1 – Role of Other Loci and GVHD</b>                         |             | 14 |
| IIC.2.1      | Aim 1 – Analysis of Non-HLA Loci  | Open        | 14 |
| IIC.2.2      | Aim 2 – Related Pairs Research Repository                                 | No Activity | 15 |
| <b>IID</b>   | <b>Clinical Research in Transplantation</b>                               |             |    |
| <b>IID.1</b> | <b>Hypothesis 1 – Clinical Research Improves Outcomes</b>                 |             | 15 |
| IID.1.1      | Aim 1 – Observational Research, Clinical Trials and NIH Transplant Center | No Activity | 15 |
| IID.1.2      | Aim 2 – Research with NMDP Donors   | No Activity | 15 |
| IID.1.3      | Aim 3 – Expand Immunobiology Research                                     | No Activity | 15 |
|              | Acronym List  |             | 16 |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008****IIA. Contingency Preparedness – Hypothesis 1:** Recovery of casualties with significant myelosuppression following radiation or chemical exposure is optimal when care plans are designed and implemented by transplant physicians

|   |   |
|---|---|
| <b>IIA.1.1 Aim 1:</b><br>Secure Interest of<br>Transplant<br>Physicians | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>• During this period 323 Basic Radiation Training (BRT) exams were submitted by RITN centers; as of September 30, 2008 a total of 1,146 BRT exams had been submitted with a passing rate exceeding 95%.</li> <li>• During this period we initiated planning for a 2009 advanced training course for RITN centers to send staff to. The course is titled Advanced Radiation Medical Emergency training and will be conducted in Oakridge, TN at the Radiation Emergency Assistance Center/Training Site (REAC/TS). Class will be held on March 26 &amp; 27. Course lessons included: <ul style="list-style-type: none"> <li>○ Basic Health Physics &amp; Radiation Protection: Part I</li> <li>○ A History of Serious Radiological Incidents: The Real Risk</li> <li>○ Health Physics &amp; Contamination Control: Part II</li> <li>○ Radiation Detection, Monitoring &amp; Protection Laboratory Exercise &amp; Quiz</li> <li>○ Diagnosis &amp; Management of the Acute Radiation Syndrome (ARS)</li> <li>○ Diagnosis &amp; Management of Internal Contamination</li> <li>○ Diagnosis &amp; Management of Acute Local Radiation Injury &amp; Case Review: Yanango Peru</li> <li>○ Radiation Sources &amp; Radiological Terrorism</li> <li>○ Radiation Emergency Area Protocol Demonstration</li> <li>○ Radiation Emergency Medical Management Drill</li> <li>○ Radiation Dose Estimations – Problem Solving Session</li> </ul> </li> </ul> |
| <b>IIA.1.2 Aim 2:</b><br>GCSF in Radiation<br>Exposure                  | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |

## QUARTER PROGRESS REPORT

### Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2008 through September 30, 2008

#### IIA.1 3 Aim 3:

Patient Assessment  
Guidelines and  
System  
Enhancements

#### Period 3 Activity:

In September CORD Link version 5.12 was released to support research completed by the CIBMTR for capturing the Cord Bank SCTOD required fields:

- Added “Bank did not test” option. Previously, the cord blood banks could not complete the form if they did not perform the test.
  - If the CBB does not have results captured for a particular test, checking the “Bank did not test” option will satisfy the field entry.
  - For cords that are shipped outside of the NMDP, and the Shipped to Other (SO) status is selected, entry of the Proposed Infusion Date, Transplant Center, and Recipient ID in the SCTOD form is now permitted.

To meet a regulatory requirement and increase product safety:

- Cord Blood Banks can send OCR forms that are scanned or hand entered by the NMDP. The data are populated into the CORD Link application. For scanned forms, a PDF is available in CORD Link. The scanned forms, when printed, now contain an ID number at the bottom of each page thus eliminating the risk of loss in chain-of-custody by linking the information to the cord blood unit.
- All import tools were modified to include the CMS question which is now required due to FDA regulations.

To increase cord blood bank efficiencies and allow users to quickly access and respond to important search information on a CBU:

- Email alerts generated by CORD Link now include a direct link to the NMDP’s connect page at “connect.nmdp.org”.

**STAR Link** and the **Do It Yourself (DIY)** application efforts were focused on simple project enhancements and preparation for future projects.

- **Statistic:** DIY Online Donor Registration through [www.marrow.org](http://www.marrow.org) resulted in a **total of 6,063** between 1/1/08 – 10/06/08.

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|  |   |
|--|---|
| <b>IIA 1.4 Aim 4:</b><br>National Data Collection Model  | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>FormsNet v2.6.1 and v2.6.2 were released during the previous quarter including a number of bug fixes and enhancements including a major cleanup of forms tracking and internationalizations enhancements.</li> <li>AGNIS has been released to production for forms 2900 and 2450 (death form and pre-TED). The data curation effort to register all 11,000 data elements in the caDSR is making steady progress with collaboration with a number of curators at the Minneapolis and Milwaukee campuses of CIBMTR and NCI.</li> </ul>   |
| <b>IIA. Contingency Preparedness – Hypothesis 2:</b> Coordination of the care of casualties who will require hematopoietic support will be essential in a contingency situation. |   |
| <b>IIA.2.1 Aim 1:</b><br>Contingency Response Network  | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>Finalized agreements for the FY09 project period for RITN</li> <li>Identified five transplant centers to invite to participate in RITN</li> <li>Initiated planning for the 2009 RITN Educational Conference</li> <li>Exercises: RITN centers continued to conduct self directed tabletop exercises based on the scenario provided to them by the NMDP and submit answers to key questions via the Internet once complete.</li> <li>Meetings: Held three (3) conference calls with RITN centers to assist in completion of required tasks and to improve integration into the network.</li> <li>Presented “Radiation Injury Treatment Network®: Hematology Physicians Preparing for a Mass Casualty Marrow Toxic Incident” at the Indo-US Workshop on Medical Countermeasures for Radiation Injury: Current and Evolving Technologies held from 17 – 20 August, 2008 in New Delhi, India.</li> <li>RITN centers were identified as an asset to be called upon during both the Democratic National Convention in Denver, CO and the Republican National Convention in St. Paul, MN. <ul style="list-style-type: none"> <li>Local as well as regional centers were identified to respond to an incident.</li> </ul> </li> </ul> |



**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|  |  |
|--|--|
|  | <ul style="list-style-type: none"> <li>Assistant Secretary of Preparedness and Response (DHHS) was provided with 24 hour contact information for the RITN Control Team in Minneapolis as well as contacts at each RITN center.</li> </ul>  |
| <b>IIA.2.2 Aim 2:</b><br>Sibling Typing<br>Standard Operating<br>Procedures  | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period</li> </ul>  |
| <b>IIA. Contingency Preparedness – Hypothesis 3:</b> NMDP's critical information technology infrastructure must remain operational during contingency situations that directly affect the Coordinating Center. |  |
| <b>IIA.3.1 Aim 1:</b><br>I.S. Disaster<br>Recovery   | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>Began planning efforts to retro fit the coordinating center server room.</li> </ul>   |
| <b>IIA.3.2 Aim 2:</b><br>Critical Facility and<br>Staff Related<br>Functions   | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li><b>Business Continuity Planning:</b> <ul style="list-style-type: none"> <li>Emergency communications: <ul style="list-style-type: none"> <li>Satellite telephone connectivity issues continue to cause problems at all RITN center locations. Global Star (satellite phone service provider) states that many satellites are aging and being deactivated and that they will be replaced in the future. With-in the emergency communication sector hopes are not high that Global Star will be able to accomplish this with the economy in the current state it is in.</li> </ul> </li> <li>Completed the development of the Business Impact Analysis (BIA) with key NMDP operational departments, identifying critical areas that would have high impact to operations if rendered inoperable.</li> <li>Conducted business continuity site visits to two (2) NMDP operated donor centers. Distributed Business Continuity Action Guides, reviewed procedures in place, and discussed methods to improve preparedness at each location.</li> <li>Continued to develop a business continuity plan incorporating a Critical Staff Recovery Site (CSRS) with no initial cost to the organization</li> </ul> </li> </ul> |

## QUARTER PROGRESS REPORT

## Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2008 through September 30, 2008

**IIB. Rapid Identification of Matched Donors – Hypothesis 1:** Increasing the resolution and quality of the HLA testing of volunteers on the registry will speed donor selection.

|   |  |
|---|--|
| <b>IIB.1.1 Aim 1:</b><br>Increase Registry Diversity            | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>The NMDP will continue to focus on educating and motivating racial and ethnic minorities about the opportunity to save lives by joining the Registry and becoming a potential adult marrow donor for a patient in need. In support of this effort, we develop and produce a complete line of educational materials targeting multicultural communities. These materials are used by our adult donor recruitment teams to engage sponsors and potential Registry members in supporting our mission. Materials produced during this period included customizable posters used to create an emotional bond between potential Registry members and patients in need and promote recruitment drive events, as well as a reprint of the Chinese version of our consent form.</li> </ul> |
| <b>IIB.1.2 Aim 2:</b><br>Evaluate HLA-DRB1 High Res typing      | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>This task is closed.</li> </ul>   |
| <b>IIB.1.3 Aim 3:</b><br>Evaluate HLA-C Typing of Donors        | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>This task is closed.</li> </ul>   |
| <b>IIB.1.4 Aim 4:</b><br>Evaluate Buccal Swabs                  | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>   |
| <b>IIB 1.5 Aim 5:</b><br>Enhancing HLA Data for Selected Donors | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>   |
| <b>IIB 1.6 Aim 6:</b><br>Maintain a Quality Control Program     | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>   |

# QUARTER PROGRESS REPORT

## Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2008 through September 30, 2008

**IIB. Rapid Identification of Matched Donors – Hypothesis 2:** Primary DNA typing data can be used within the registry to improve the quality and resolution of volunteer donor HLA assignments.

|  |  |
|--|--|
| <b>IIB 2.1 Aim 1:</b><br>Collection of Primary Data          | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>New versions of One Lambda/Luminex SSO kits were registered during the last quarter A, B, C, DRB1 kit revisions and the <b>new</b> high-definition HLA-A, -B and –DRB1 kits</li> <li>A series of conference calls were held to discuss the SBT reporting format and provisions for using SBT for ambiguity resolution. We have a laboratory sending test messages and intend to be able to process their messages in the next quarter.</li> </ul> |
| <b>IIB 2.2 Aim 2:</b><br>Validation of Logic of Primary Data | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>This task is closed.</li> </ul>   |
| <b>IIB 2.3 Aim 3:</b><br>Reinterpretation of Primary Data    | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>This task is closed.</li> </ul>   |
| <b>IIB 2.4 Aim 4:</b><br>Genotype Lists & Matching Algorithm | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>   |

**IIB. Rapid Identification of Matched Donors – Hypothesis 3:** Registry data on HLA allele and haplotype frequencies and on the nuances of HLA typing can be used to design computer algorithms to predict the best matched donor.

|  |  |
|--|--|
| <b>IIB.3.1 Aim 1:</b><br>Phase I of EM Haplotype Logic | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>No activity specific to this Aim for this period.</li> </ul>  |
| <b>IIB 3.2 Aim 2:</b><br>Enhancement of EM Algorithm   | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>A manuscript entitled “Re-creation of the Genetic Composition of a Founder Population” was accepted for publication in Human Genetics</li> <li>A manuscript has been drafted entitled “The HLA genetics of Jewish populations” and has</li> </ul> |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|   |  |
|---|--|
|   | <p>undergone revision for submission during the next quarter</p> <ul style="list-style-type: none"> <li>Three abstracts were presented at the 15th IHIWS conference (“High resolution reconstruction of HLA haplotypes in Native Americans”, “HLA haplotype diversity in Brazil” and “Anthropological Insights from a Novel Visualization and Clustering Tool for HLA Haplotypes and Populations”</li> </ul>   |
| <b>IIB 3.3 Aim 3:</b><br>Optimal Registry<br>Size Analysis          | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>Study design work has progressed on the clinical validation of 8/8 matching including the development of statistical power computations.</li> <li>A meeting was held with representatives from DKMS and they confirmed participation in the study which means we will be able to type all DoD, DKMS and NMDP donors with samples which represents the vast majority of donors on these searches.</li> </ul>                              |
| <b>IIB 3.4 Aim 4:</b><br>Target Under-<br>represented<br>Phenotypes | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>Sent staff to annual GIS software (ESRI) user-group meeting</li> <li>GIS software has been purchased and installed along with census resource databases</li> <li>A prototype kernel density (heat) map was produced to show the geographical distribution of the most common African American broad HLA phenotype.</li> <li>A full ZIP code update was performed on the geocoding database for use in ongoing ad-hoc analyses</li> </ul> |
| <b>IIB 3.5 Aim 5:</b><br>Bioinformatics Web<br>Site                 | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>This task is closed.</li> </ul>  |
| <b>IIB 3.6 Aim 6:</b><br>Consultants to<br>Improve Algorithm        | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>  |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

**IIB. Rapid Identification of Matched Donors – Hypothesis 4:** Reducing the time and effort required to identify closely matched donors for patients in urgent need of HSC transplants will improve access to transplantation and patient survival in the context of a contingency response and routine patient care.

**IIB.4.1 Aim 1:**  
Expand Network  
Communications

**Period 3 Activity:****Traxis Upgrade July 15, 2008**

Traxis was upgraded on July 15<sup>th</sup> to address defects related to patient look ups and email notifications (sending them to NMDP Search Coordinators when a search request was processed).

**SEARCH Link™ application upgrades**

To aid the Search and Transplant Department in maintaining patient safety:

- Actions Codes were implemented for Cooperative Registry Donors and CBUs to improve operational efficiencies. These codes will function like the domestic donors and CBUs. Some Action Codes were retired.
- The Working TC Request tab no longer displays on the Request Detail screen for Rejected Electronic Workup requests.
- The Request Detail date fields for rejected requests are grayed out and made not editable to eliminate accidental changes.
- Requests for the same source in the search detail screen will continue to sort by date, with the most recent date displaying first. If there are multiple requests for the same source on the same day, the requests will sort in the following status order: 1.) Pending requests 2.) Open requests 3.) Resolved requests 4.) Closed requests 5.) Rejected requests.
- Functionality was restored to display a pop-up window indicating active sources exist on a search if a user attempts to cancel the search for a source type. The search will not be cancelled.

To improve operational efficiencies for the Search and Transplant Department:

- Find feature was implemented to easily filter patients with Coop action items.

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

- The *Email* field was implemented as required in the User Maintenance screen when adding a new user or making edits to an existing user.

To facilitate best matches for patients for transplant centers and the Search and Transplant Services department:

- Functionality was restored to display match grades for manually entered Cooperative Registry Donors and CBUs.
- Functionality was restored to set the status of Cooperative Registry Cords released as infused to NA.
- Functionality was restored to display Cooperative Registry Cord and Donor IDs, along with the Action Code descriptions, if applicable, in the Confirm multiple selection pop-up when multiple sources are released.
- Functionality was restored to prohibit an international transplant center to request a CBU from an international cord blood bank. Cord Blood Bank 191, StemCyte Taiwan National Cord Blood Center, is an exception to this rule.
- Two-day PBSC collections are shown as one donation on the Donor Info screen under Prev. Donations to lessen confusion.

**STAR2 Application Upgrade**

To increase operational efficiencies for the Search and Transplant Department:

Action codes that are no longer active/utilized were retired

To increase the reliability and timeliness of notifying network members of search activity:

Improvements were made in the functionality to send data to member centers. These improvements will increase the system capacity for handling large transaction volumes and detect data integrity issues (like incoming & outgoing duplicate transactions, gaps in sequence numbers).

## QUARTER PROGRESS REPORT

## Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2008 through September 30, 2008

|  |   |
|--|---|
| <b>IIB.4.2 Aim 2:</b><br>Central Contingency Management                          | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>• The medical education department continued to execute education to referring physicians on the role and timing of transplantation. In this period, we issued a <i>Special edition of Advances in Transplantation</i> to 10,000 hematologists/oncologists. This issue covered key research presented at the 2008 European Blood and Marrow Transplantation meeting. By publishing this newsletter, NMDP brings the latest in transplant research and advances to the broader referral audience.</li> <li>• NMDP also continued the initiative to build awareness and use of the NMDP/ASBMT guidelines for <i>Recommended Timing for Transplant Consultation</i> and the <i>Post-Transplant Care Guidelines</i>. These two guidelines are now distributed in a tool kit, allowing referring physicians to understand both referral and post-transplant care recommendations, in order to provide optimal care to their patients. The post-transplant care kit also includes a highly regarded photo atlas for early assessment and diagnosis of GVHD. By recognizing GVHD symptoms early, care can be delivered to help prevent more extensive complications. In this period, 10,000 referring physicians were notified of the availability of the guidelines and were offered multiple ways to order the guidelines. Analysis of the result of the direct mail and e-mail campaign are underway.</li> </ul> |
| <b>IIB.4.3 Aim 2:</b><br>Benchmarking Analysis                                   | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>• This task is closed.</li> </ul>  |
| <b>IIB.4.4 Aim 2:</b><br>Expand Capabilities of Collection and Apheresis Centers | <b>Period 3 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

**IIC. Immunogenetic Studies – Hypothesis 1:** HLA mismatches may differ in their impact on transplant outcome, therefore, it is important to identify and quantify the influence of specific HLA mismatches. In contingency situations it will not be possible to delay transplant until a perfectly matched donor can be found.

**IIC.1.1 Aim 1:**  
Donor Recipient Pair  
Project

**Period 3 Activity:**

In 1994 a retrospective Donor/Recipient Pair HLA typing project to characterize class I and class II alleles of donor/recipient paired samples from NMDP's Repository was initiated. The goals of this ongoing research project are to assay the impact of DNA-based HLA matching on unrelated donor transplant outcome, develop strategies for optimal HLA matching, evaluate the impact of matching at alternative HLA loci on transplant outcome and finally to promote the development of DNA-based high resolution HLA typing methodologies.

- The contracts for SG21 (500 pairs) testing was awarded to four labs. SG21 contracts will include intermediate and high resolution HLA and also presence/absence testing for 14 KIR loci (2DL1-5, 2DS1-5, 3DL1-3 and 3DS1).
- The project period for SG21 began September 1, 2008 and continues until December 31, 2008.

**IIC. Immunogenetic Studies – Hypothesis 2:** Even when patient and donor are HLA matched, GVHD occurs so other loci may play a role.

**IIC 2.1 Aim 1:**  
Analysis of non-  
HLA loci

**Period 3 Activity:**

Continued development of the IPR (Immunobiology Project Results) database occurred during the past quarter. This database will replace the existing HLA donor/recipient pairs database and have the capacity to process KIR, SNPs, or any other Immunobiological tests. For sample group twenty one (SG21), it will mirror HLA processing in the current system and incorporate KIR processing (which is not available in the current system).

- The Scientific Services and Bioinformatics departments continued to collaborate on the design and development of the IPR database application and tools to support immunogenetic testing projects
- A software-developer contractor has worked on implementing the acceptance, validation, storage of incoming data via Histoimmunogenetics Markup Language (HML). The next phase will develop



**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|  |  |
|--|--|
|  | <p>and test the extension of the process to genotype lists (of immediate importance for KIR data) and the reporting of the whole process. It is scheduled for completion late next quarter. [The development of genotype lists also requires enhancements of NDMP databases/software on which IPR depends.]</p> <ul style="list-style-type: none"> <li>• Another software-developer contractor has worked on a implementing a web-browser-based application which will allow users to view typing results as stored in the database. It is scheduled for completion next quarter.</li> <li>• Analysis of processing rules (lab-to-lab comparison, ambiguity analysis, data audits) has been put on hold until data-loading development is completed. It is scheduled to resume early 2009.</li> <li>• Specifications are being written to transfer data from the old system to IPR. They are scheduled for completion next quarter.</li> <li>• Work continued on a prototype project to recreate informational data stores.</li> </ul> |
| <b>IIC 2.2 Aim 2:</b><br>Related Pairs<br>Research Repository  | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |
| <b>IID. Clinical Research in Transplantation – Hypothesis 1:</b> Clinical research in transplantation improves transplant outcomes and supports preparedness for a contingency response. |  |
| <b>IID.1.1 Aim 1:</b><br>Observational<br>Research, Clinical<br>Trials and NIH<br>Transplant Center  | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |
| <b>IID.1.2 Aim 2:</b><br>Research with<br>NMDP Donors  | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |
| <b>IID.1.3 Aim 3:</b><br>Expand Immuno-<br>biology Research  | <p><b>Period 3 Activity:</b></p> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>  |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008****ACRONYM LIST**

|         |   |         |  |
|---------|---|---------|--|
| AABB    | American Association of Blood Banks                               | IND     | Investigational New Drug   |
| AML     | Acute Myelogenous Leukemia  | ICRHER  | International Consortium for Research on Health Effects of Radiation |
| ARS     | Acute Radiation Syndrome (also known as Acute Radiation Sickness) | IS      | Information Services   |
| ASBMT   | American Society for Blood and Marrow Transplantation             | IT      | Information Technology   |
| ASHI    | American Society for Histocompatibility and Immunogenetics        | IRB     | Institutional Review Board   |
| B-LCLs  | B-Lymphoblastoid Cell Lines                                       | KIR     | Killer Immunoglobulin-like Receptor                                  |
| BMT CTN | Blood and Marrow Transplant - Clinical Trials Network             | NCI     | National Cancer Institute  |
| BRT     | Basic Radiation Training  | MHC     | Major Histocompatibility Complex                                     |
| C&A     | Certification and Accreditation                                   | MICA    | MHC Class I-Like Molecule, Chain A                                   |
| CBMTG   | Canadian Blood and Marrow Transplant Group                        | MICB    | MHC Class I-Like Molecule, Chain B                                   |
| CBB     | Cord Blood Bank   | MUD     | Matched Unrelated Donor  |
| CBC     | Congressional Black Caucus  | NCBM    | National Conference of Black Mayors                                  |
| CBS     | Canadian Blood Service  | NIH     | National Institutes of Health  |
| CBU     | Cord Blood Unit   | NIMS    | National Incident Management System                                  |
| CHTC    | Certified Hematopoietic Transplant Coordinator                    | NK      | Natural Killer   |
| CIBMTR  | Center for International Blood & Marrow Transplant Research       | NMDP    | National Marrow Donor Program  |
| CLIA    | Clinical Laboratory Improvement Amendment                         | NRP     | National Response Plan   |
| CME     | Continuing Medical Education                                      | NST     | Non-myeloablative Allogeneic Stem Cell Transplantation               |
| COG     | Children's Oncology Group   | OCR/ICR | Optical Character Recognition/Intelligent Character Recognition      |
| CREG    | Cross Reactive Groups   | OIT     | Office of Information Technology                                     |
| CT      | Confirmatory Testing  | OMB     | Office of Management and Budget                                      |
| CTA     | Clinical Trial Application  | ONR     | Office of Naval Research   |

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2008 through September 30, 2008**

|       |  |         |  |
|-------|--|---------|--|
| DIY   | Do it yourself   | PBMC    | Peripheral Blood Mononuclear Cells                                       |
| DKMS  | Deutsche Knochenmarkspenderdatei                                 | PBSC    | Peripheral Blood Stem Cell   |
| DMSO  | Dimethylsulphoxide   | PCR     | Polymerase Chain Reaction  |
| DNA   | Deoxyribonucleic Acid  | PSA     | Public Service Announcement  |
| D/R   | Donor/Recipient  | QC      | Quality control  |
| EBMT  | European Group for Blood and Marrow Transplantation              | RCC     | Renal Cell Carcinoma   |
| EM    | Expectation Maximization   | RCI BMT | Resource for Clinical Investigations in Blood and Marrow Transplantation |
| EMDIS | European Marrow Donor Information System                         | REAC/TS | Radiation Emergency Assistance Center/Training Site                      |
| FBI   | Federal Bureau of Investigation                                  | RFP     | Request for Proposal   |
| FDA   | Food and Drug Administration                                     | RFQ     | Request for Quotation  |
| Fst   | Fixation Index   | RITN    | Radiation Injury Treatment Network                                       |
| GETS  | Government Emergency Telecommunications Service                  | SBT     | Sequence Based Typing  |
| GCSF  | Granulocyte-Colony Stimulating Factor (also known as filgrastim) | SCTOD   | Stem Cell Therapeutics Outcome Database                                  |
| GvHD  | Graft vs Host Disease  | SG      | Sample Group   |
| HHS   | Health and Human Services  | SSP     | Sequence Specific Primers  |
| HIPAA | Health Insurance Portability and Accountability Act              | SSOP    | Sequence Specific Oligonucleotide Probes                                 |
| HLA   | Human Leukocyte Antigen  | STAR®   | Search, Tracking and Registry  |
| HML   | Histoimmunogenetics Mark-up Language                             | TC      | Transplant Center  |
| HR    | High Resolution  | TED     | Transplant Essential Data  |
| HRSA  | Health Resources and Services Administration                     | TNC     | Total Nucleated Cell   |
| HSC   | Hematopoietic Stem Cell  | TSA     | Transportation Security Agency   |
| IBWC  | Immunobiology Working Committee                                  | URD     | Unrelated Donor  |
| IDM   | Infectious Disease Markers                                       | WMDA    | World Marrow Donor Association   |
| IHWG  | International Histocompatibility Working Group                   | WU      | Work-up  |
|       |  |         |  |